The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFFWD.L Regulatory News (FFWD)

  • There is currently no data for FFWD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sale of Investments in Kanabo and Cellular Goods

11 Mar 2021 08:00

RNS Number : 9353R
FastForward Innovations Limited
11 March 2021
 

FastForward Innovations Ltd / AIM: FFWD / Sector: Closed End Investments

11 March 2021

FastForward Innovations Ltd ("FastForward", "the Company" or, "FFWD")

 

Sale of Investments in Kanabo and Cellular Goods

 

FastForward Innovations Ltd, the AIM quoted company focusing on making investments in fast growing and industry leading businesses, is pleased to announce that following the announcements on 16 February and 1 March respectively regarding the Company's investments in Kanabo Group Plc ('Kanabo') and Cellular Goods Plc ('Cellular Goods'), FastForward has now sold its entire holding in both companies providing the Company with gross profits of £194,414.39.

 

Highlights

· Sale of shares in Kanabo resulted in a profit of £139,851.68, an increase of 223% in value since the Company's original investment

· Sale of shares in Cellular Goods resulted in a profit of £54,562.71, an increase of 315% in value since the Company's original investment

· Proceeds will be used to make further investments in accordance with FastForward's investing policy

 

Ed McDermott, CEO of FastForward Innovations, commented: "Whilst we were disappointed to be heavily scaled back due to both placings being oversubscribed, we are delighted to have made such significant returns on our investments in Kanabo and Cellular Goods in a short timeframe. With our already strong balance sheet, the proceeds from these sales, along with the significant funds to be received from the sale of EMMAC as announced yesterday, will put FastForward in a very strong cash position and enable us to invest in other new and exciting businesses that will bring value to shareholders. We hope to provide further updates on developments in this regard in due course."

 

Further Information

As announced on 16 February 2021, FastForward invested £62,500 as part of a £6 million oversubscribed placing at a price of 6.5 pence undertaken by Kanabo, which commenced trading on the London Stock Exchange on the same day (LSE: KNB), following a reverse takeover of Spinnaker Opportunities Plc.

 

FastForward completed the sale of its entire holding of 961,538 shares on 8 March providing the Company with total proceeds of £202,684.15 equating to an average net sale price of £0.211 per share. As such, FastForward has made a profit of £139,851.68, which is a total return of 3.23 times the original investment.

 

As announced on 1 March 2021, FastForward invested approximately £17,215 as part of a heavily oversubscribed £13 million placing at a price of 5 pence undertaken by Cellular Goods, which commenced trading on the London Stock Exchange on 26 February 2021 (LSE: CBX).

 

FastForward completed the sale of its entire holding of 344,277 shares in Cellular Goods on 4 March 2021 providing the Company with total proceeds of £71,862.63 equating to an average net sale price of £0.209 per share. As such, FastForward has made a profit of £54,562.71, which is a total return of 4.15 times the original investment.

 

For further information on the Company please visit www.fstfwd.co or contact:

Ed McDermott / Lance de Jersey

FastForward Innovations Ltd

Email: info@fstfwd.co

 

James Biddle / Roland Cornish

Beaumont Cornish Limited,

Nomad

 

Tel: +44 (0) 207 628 3396

 

Isabella Pierre / Damon Heath

Shard Capital Partners LLP

 

Tel: (0)207 186 9927

Isabel de Salis / Beth Melluish

St Brides Partners Ltd,

Financial PR

Tel: +44 (0)207 236 1177

 

Notes

FastForward Innovations is an AIM quoted investment company focused primarily on disruptive high growth life sciences and technology businesses particularly within the medical cannabis arena. The Company's strategy is to identify early stage opportunities that have an upcoming investment catalyst and grow its portfolio in terms of value whilst limiting the number of investee companies to a level where relevant time can be devoted to each.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DISKZGMFNMVGMZG
Date   Source Headline
25th Feb 20207:00 amRNSInvestee Company Update: EMMAC Life Sciences
18th Feb 20207:00 amRNSInvestee Company Update: EMMAC Life Sciences
11th Feb 20207:00 amRNSUpdated Key Information Document
31st Jan 20201:30 pmRNSInvestee Company Update: Portage Biotech Inc.
8th Jan 20207:00 amRNSDisposal of Interest in Cryptologic Corp
7th Jan 20207:00 amRNSBoard Appointment
3rd Jan 20201:15 pmRNSInvestee Company Update: Portage Biotech Inc.
11th Dec 20197:00 amRNSHalf-year Report
5th Dec 20192:45 pmRNSTR-1 Notification
19th Nov 20197:00 amRNSLorne Abony appointed as Chairman of EMMAC
16th Oct 20197:00 amRNSInvestee Company Update: EMMAC Life Sciences
15th Oct 20197:00 amRNSInvestee Company Update: Factom inc.
10th Oct 20199:25 amRNSResult of 2019 AGM
27th Sep 20194:31 pmRNSDirector Dealing in the Company
27th Sep 20197:00 amRNSInvestee Company Update : Fralis LLC (Leap Gaming)
26th Sep 201911:21 amRNSInvestee Company Update : Cryptologic Corp
16th Sep 201911:52 amRNSTR-1 Notification of major holdings
11th Sep 20198:00 amRNSResults for the year ended 31st March 2019
11th Sep 20198:00 amRNSNotice of 2019 Annual General Meeting
22nd Aug 201912:01 pmRNSDirectorate Change
19th Aug 20199:23 amRNSJuvenescence closes Series B funding
12th Aug 20193:02 pmRNSInvestee Company Update-Cryptologic issues loan
12th Aug 201910:11 amRNSPortage Trading Suspended
6th Aug 20194:42 pmRNSInvestee Company Update: Cryptologic Corp
30th Jul 201911:07 amRNSSAFE Agreement with Factom, Inc. Extended
25th Jul 20198:17 amRNSFactom Inc SAFE Agreement temporary extension
18th Jul 201911:20 amRNSInvestee Company Update: Regent Pacific on Yooya
16th Jul 20199:13 amRNSInvestee Company Update:EMMAC acquires Terre Verde
11th Jul 20193:00 pmRNSDisposal of interest in Intensity Therapeutics Inc
9th Jul 201910:51 amRNSInvestee Company Update: EMMAC enters new Market
26th Jun 20198:56 amRNSInvestee Company Update: Intensity Therapeutics
29th May 20193:43 pmRNSInvestee Company Update: Offer for Yooya
13th May 201910:21 amRNSDisposal of interest in Vemo Education Inc.
18th Apr 20197:00 amRNSInvestee Company Update: Intensity Therapeutics
4th Apr 20199:51 amRNSTR1 - Correction
3rd Apr 20194:00 pmRNSTR:1 Regent Mercantile Holdings Limited
20th Mar 201911:00 amRNSCompletion of £2 million investment in EMMAC
7th Mar 20194:03 pmRNS£2 million investment in EMMAC Life Sciences
15th Jan 20193:45 pmRNSJuvenescence Series B Funding
3rd Jan 201911:47 amRNSBoard Appointment
12th Dec 201812:52 pmRNSHalf-year Report
3rd Dec 20187:00 amRNSInvestee Company Update: Factom and Yooya
14th Nov 20181:31 pmRNSInvestee Company Update: Factom Inc
22nd Oct 201812:24 pmRNSIntensity Therapeutics Inc Update
12th Sep 20186:12 pmRNSResult of AGM
10th Sep 20189:16 amRNSHolding(s) in Company
22nd Aug 20188:08 amRNSDirector Dealing
3rd Aug 201812:48 pmRNSShareholder update
3rd Aug 20188:00 amRNSPlacing
1st Aug 201812:05 pmRNSResponse to Media Speculation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.